ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

ClinicalTrials.gov ID: NCT00038467

Public ClinicalTrials.gov record NCT00038467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

Study identification

NCT ID
NCT00038467
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
4,740 participants

Conditions and interventions

Interventions

  • Exemestane Drug
  • Tamoxifen Drug

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 1998
Primary completion
May 31, 2003
Completion
Feb 28, 2013
Last update posted
May 6, 2014

1998 – 2013

United States locations

U.S. sites
57
U.S. states
11
U.S. cities
39
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35205
Pfizer Investigational Site Birmingham Alabama 35213
Pfizer Investigational Site Birmingham Alabama 35235
Pfizer Investigational Site Green Valley Arizona 85614
Pfizer Investigational Site Green Velley Arizona 85614
Pfizer Investigational Site Tucson Arizona 85704
Pfizer Investigational Site Tucson Arizona 85710
Pfizer Investigational Site Tucson Arizona 85712
Pfizer Investigational Site Tucson Arizona 85715
Pfizer Investigational Site Tucson Arizona 85745
Pfizer Investigational Site Boulder Colorado 80304
Pfizer Investigational Site Colorado Springs Colorado 80909
Pfizer Investigational Site Denver Colorado 80218
Pfizer Investigational Site Fort Collins Colorado 80528
Pfizer Investigational Site Lakewood Colorado 80228
Pfizer Investigational Site Thornton Colorado 80260
Pfizer Investigational Site Jacksonville Florida 32204
Pfizer Investigational Site Jacksonville Florida 32207
Pfizer Investigational Site Jacksonville Beach Florida 32250
Pfizer Investigational Site Ocala Florida 34474
Pfizer Investigational Site Orange Park Florida 32073
Pfizer Investigational Site Fishers Indiana 46037
Pfizer Investigational Site Fishers Indiana 46038
Pfizer Investigational Site Indianapolis Indiana 46219
Pfizer Investigational Site Indianapolis Indiana 46227
Pfizer Investigational Site Indianapolis Indiana IN 46219
Pfizer Investigational Site Cedar Rapids Iowa 52403
Pfizer Investigational Site Pittsfield Massachusetts 01201
Pfizer Investigational Site Albany New York 12206
Pfizer Investigational Site Latham New York 12110-0610
Pfizer Investigational Site Portland Oregon 97225
Pfizer Investigational Site Portland Oregon 97227
Pfizer Investigational Site Arlington Texas 76014-2084
Pfizer Investigational Site Bedford Texas 76022
Pfizer Investigational Site Dallas Texas 75230-2510
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Dallas Texas 75246
Pfizer Investigational Site El Paso Texas 79902
Pfizer Investigational Site El Paso Texas 79915
Pfizer Investigational Site Garland Texas 75042
Pfizer Investigational Site Houston Texas 77024
Pfizer Investigational Site Houston Texas 77029
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site Houston Texas 77074
Pfizer Investigational Site Longview Texas 75601
Pfizer Investigational Site McAllen Texas 78503
Pfizer Investigational Site Mesquite Texas 75150
Pfizer Investigational Site Odessa Texas 79761
Pfizer Investigational Site Pasadena Texas 77502
Pfizer Investigational Site Plano Texas 75075-7787
Pfizer Investigational Site San Antonio Texas 78217
Pfizer Investigational Site Sherman Texas 75090
Pfizer Investigational Site Sugar Land Texas 77479
Pfizer Investigational Site Tyler Texas 75702
Pfizer Investigational Site Weslaco Texas 78596
Pfizer Investigational Site Spokane Washington 99202
Pfizer Investigational Site Spokane Washington 99218

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 320 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00038467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 6, 2014 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00038467 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →